REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy – Ophthalmology Times

REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy  Ophthalmology Times

RCM Expert
1–2 minutes

REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy  Ophthalmology Times

Leave a Reply

Trending

Discover more from Ophthalmology News USA

Subscribe now to keep reading and get access to the full archive.

Continue reading